Bucillamine, a thiol antioxidant, prevents transplantation-associated reperfusion injury

Overview of attention for article published in Proceedings of the National Academy of Sciences of the United States of America, June 2002

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 50 news outlets
twitter: 9 X users
patent: 5 patents

wikipedia: 2 Wikipedia pages
reddit: 6 Redditors

Readers on

mendeley: 23 Mendeley

So far, Altmetric has seen 104 news stories from 50 outlets.

Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure

Stockwatch, 17 Oct 2023

TORONTO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKF…

Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure

Le Lézard, 17 Oct 2023

TORONTO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKF…

Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure

WGN9, 17 Oct 2023

TORONTO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKF…

Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure

Benzinga, 17 Oct 2023

Loading...Loading...Loading... TORONTO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd.

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 100 additional news stories.